Z
Z Squared Inc.
Period
FY 2025
Revenue
$1.36M
Net Income
$-11.92M
Total Assets
$16.15M
Equity
$13.56M
Shares Out
51.43M
Op. Cash Flow
$-8.60M
Business
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical and technology holding company that develops cell therapy platforms for cancer, autoimmune, and infectious diseases through subsidiaries SNAP Biosciences and GEAR Therapeutics, alongside majority and wholly owned entities. The biopharmaceutical division pursues preclinical and clinical-stage programs including CD38-GEAR-NK (autologous NK cell therapy), CD38-Diagnostic (in vitro diagnostic), and SNAP-CAR (universal CAR-T platform for solid tumors), with collaborations via licensing agreements and joint development arrangements. The technology division offers AI-powered marketing automation software and robotic process automation tools for digital marketing services.
Summary from 10-K filed 2026-03-19
Financials
Consolidated Statement of Income
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Total sales | 1 | 0 | 0 | 0 | 75,000 | |
| Cost of goods | 180,625 | 0 | 0 | 0 | 0 | |
| Gross profit | 1 | 0 | 0 | 0 | 75,000 | |
| Research and development expense | 1 | 2 | 7 | 20,887 | 0 | |
| Salary expense | 2 | 2 | 1 | — | — | |
| Amortization expense | 1 | 1 | — | — | — | |
| Professional services expense | 8 | 3 | 11 | 31 | — | |
| Stock based compensation expense | 1 | 1 | — | — | — | |
| General and administrative expenses | 1 | 945,641 | — | — | — | |
| Selling and marketing expense | 105,000 | 0 | 12,710 | 8,331 | 2,918 | |
| Total cost of operations | 14 | 10 | 21 | 34 | 14 | |
| LOSS FROM OPERATIONS | −13 | −10 | −21 | −34 | −14 | |
| Interest expense | −96,744 | −246,116 | −107,685 | — | — | |
| Interest income | 116,495 | 234,742 | — | — | — | |
| Amortization of debt discount | −545,635 | −216,189 | — | — | — | |
| Gain on forfeiture of customer deposit | 115,000 | 0 | — | — | — | |
| Other income (expense), net | 7,004 | −16,444 | −220,477 | 98,701 | — | |
| Unrealized gain on marketable securities | 76,596 | 0 | — | — | — | |
| Unrealized loss on investments | −163,500 | 0 | — | — | — | |
| Loss on write down of assets | 0 | −37,257 | 0 | — | — | |
| Gain (loss) on extinguishment of debt | 159,035 | −200,000 | — | — | — | |
| Change in fair value of derivative liabilities | 1 | −341,660 | 567,750 | — | — | |
| TOTAL OTHER INCOME (EXPENSE), net | 766,306 | −822,924 | 224,588 | −3 | 596,653 | |
| LOSS BEFORE INCOME TAXES | −12 | −11 | −21 | −38 | −13 | |
| PROVISION FOR INCOME TAXES (BENEFIT) | 0 | 0 | 0 | 0 | 0 | |
| NET LOSS | −12 | −11 | — | — | — | |
| NET LOSS ATTRIBUTABLE TO NON-CONTROLLING INTERESTS | −360,177 | −196,960 | 0 | — | — | |
| NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS | −12 | −11 | −21 | −38 | −13 | |
| Loss per share, basic | −2.81 | −5.56 | −16.56 | −2.63 | −1.23 | |
| Loss per share, fully diluted | −2.81 | −5.56 | −16.56 | −2.63 | −1.23 | |
| Weighted average number of common shares outstanding, basic | 4 | 2 | 1 | 14 | 11 | |
| Weighted average number of common shares outstanding, diluted | 4 | 2 | 1 | 14 | 11 |
Consolidated Balance Sheet
As of · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash | 6 | 532,885 | 1 | — | — | |
| Marketable securities | 676,596 | 0 | — | — | — | |
| Interest receivable | 7,348 | 0 | 38,978 | — | — | |
| Prepaid assets | 991,903 | 518,407 | 241,601 | 142,356 | 0 | |
| TOTAL CURRENT ASSETS | 7 | 1 | 2 | 4 | 2 | |
| Furniture and fixtures, net | 9,873 | 10,460 | 11,306 | 12,542 | 13,926 | |
| Investments | 8 | 6 | 0 | — | — | |
| Intangible assets, net | 361,250 | 541,875 | — | — | — | |
| Co-development rights, net | 554,167 | 2 | — | — | — | |
| Right of use asset, net of accumulated amortization | 18,399 | 59,783 | 97,571 | 58,914 | 17,925 | |
| Total other assets | 9 | 8 | 3 | 4 | 5 | |
| TOTAL ASSETS | 16 | 9 | 5 | 8 | 7 | |
| Accounts payable | 888,755 | 1 | 1 | 99,021 | 134,092 | |
| Accrued expenses | 41,054 | 736,884 | 555,950 | 181,998 | 199,126 | |
| Convertible notes payable, net of debt discount of $0 and $435,635 | 0 | 1 | 875,000 | — | — | |
| Convertible notes payable, in default | 100,000 | 100,000 | 100,000 | — | — | |
| Right of use liability, current portion | 18,875 | 42,305 | 38,047 | 41,618 | 14,724 | |
| Customer deposit | 599,455 | 0 | — | — | — | |
| Derivative liability | 0 | 1 | 0 | — | — | |
| Other current liabilities | 120,000 | 235,000 | 0 | — | — | |
| TOTAL CURRENT LIABILITIES | 2 | 5 | 3 | 2 | 3 | |
| SBA loan payable | 150,000 | 150,000 | 150,000 | 150,000 | 2 | |
| Derivative liability warrants | 167,625 | 359,250 | 557,250 | 1 | 0 | |
| Right of use liability, non-current portion | 0 | 18,875 | 61,179 | 14,723 | 0 | |
| TOTAL LONG TERM LIABILITIES | 317,625 | 528,125 | 768,429 | 1 | 2 | |
| TOTAL LIABILITIES | 2 | 5 | 4 | 3 | 4 | |
| Common stock, $0.0001 par value, 150,000,000 shares authorized, 5,746,948 and 2,116,191 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | 575 | 212 | 179 | 1,957 | 1,196 | |
| Additional paid-in capital | 127 | 103 | 92 | 71 | 30 | |
| Common stock subscribed | 0 | 541,875 | 0 | — | — | |
| Subscription receivable | −4 | −2 | −4 | — | — | |
| Accumulated deficit | −110 | −98 | −87 | −66 | −28 | |
| TOTAL STOCKHOLDERS' EQUITY - CONTROLLING INTERESTS | 14 | 3 | 813,964 | 4 | 2 | |
| TOTAL STOCKHOLDERS' EQUITY - NONCONTROLLING INTERESTS | 506,163 | 485,102 | 0 | — | — | |
| TOTAL STOCKHOLDERS' EQUITY | 14 | 4 | 813,963 | 4 | — | |
| TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | 16 | 9 | 5 | 8 | 7 |
Consolidated Statement of Cash Flows
Year Ended · In millions, except per-share amounts
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation and amortization | 1 | 1 | 1 | 1 | 447,413 | |
| Right of use asset amortization | 41,385 | 37,788 | — | — | — | |
| Non-cash revenue | −1 | 0 | — | — | — | |
| Stock based compensation | 1 | 1 | 477,503 | — | — | |
| Shares issued for non-employee services | 4 | 1 | 4 | 5 | 3 | |
| Warrants issued for services | 824,295 | 8,150 | 3 | 24 | 5 | |
| Change in fair value of derivative liability | −906,430 | 539,660 | — | — | — | |
| Change in fair value of derivative liability warrants | −191,625 | −198,000 | — | — | — | |
| Loss on shares issued for conversion of debt | 0 | 77,250 | 0 | — | — | |
| (Gain) loss on extinguishment of debt | −159,035 | 200,000 | — | — | — | |
| Forgiveness of interest | 0 | 37,257 | −38,978 | 0 | — | |
| Interest receivable | −7,348 | −234,742 | −38,978 | — | — | |
| Prepaid assets | −473,497 | −118,472 | 90,755 | — | 43,482 | |
| Accounts payable | −381,012 | −149,935 | 1 | −35,071 | — | |
| Accrued expenses | −440,889 | 180,934 | 376,878 | −17,128 | −424,020 | |
| Right of use liability | −42,306 | −38,047 | −30,324 | 628 | −1,317 | |
| Other current liabilities | −115,000 | 235,000 | 0 | — | — | |
| NET CASH USED IN OPERATING ACTIVITIES | −9 | −7 | −7 | −4 | −4 | |
| NET CASH USED IN INVESTING ACTIVITIES | 0 | 0 | 0 | 0 | −2 | |
| Proceeds from notes payable | 990,000 | 2 | 650,000 | 0 | 77,595 | |
| Repayment of notes payable | −218,750 | −650,969 | — | — | — | |
| Shares issued for SEPA | 3 | 0 | — | — | — | |
| Shares issued for cash | 5 | 100,000 | 500,000 | 3 | 10 | |
| Warrants issued for cash | 0 | 500,000 | 200,000 | 0 | — | |
| Pre-funded warrants exercise | 900 | 0 | — | — | — | |
| Preferred stock offering | 5 | 4 | — | — | — | |
| NET CASH PROVIDED BY FINANCING ACTIVITIES | 14 | 6 | 5 | 5 | 8 | |
| NET INCREASE (DECREASE) IN CASH | 5 | −936,249 | −2 | 2 | 2 | |
| Interest paid | 8,772 | 8,772 | 0 | 0 | 0 | |
| Taxes paid | 0 | 0 | 0 | 0 | 0 | |
| Subscriptions receivable | 4 | 2 | — | — | — | |
| Shares issued for the conversion of debt | 3 | 951,684 | — | — | — | |
| Shares issued for investment | 1 | 0 | — | — | — |
Filings
Filing historySign up free to browse every 10-K, 10-Q, 8-K, and proxy this filer has submitted to the SEC.Sign up free · Upgrade to Pro
Material Events
Material EventsTrack every 8-K filing and material event — AI-summarized, timelined, and alertable.Sign up free · Upgrade to Pro
Insiders
Insider ActivitySee executive buy/sell windows and insider trade activity over rolling 30/90/365-day windows.Sign up free · Upgrade to Pro
Institutional Holders
Institutional HoldersSee which funds hold this stock and track position changes quarter over quarter.Sign up free · Upgrade to Pro
Frequently asked questions
What is Z Squared Inc.'s CIK number?
Z Squared Inc.'s SEC CIK number is 0001759186 (1759186). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find Z Squared Inc.'s SEC filings?
All of Z Squared Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.